I joined the Molecular Imaging and Theranostics lab in 2022 as a PhD student. My research focuses on the drug delivery system.

In clinical practice, timely intravenous administration (i.v.) of anti-thrombotic or fibrinolytic drugs allows reperfusion of occluded arteries. However, large doses are required to achieve for significant thrombolytic effects because they have a short circulation half-life of 7–20 min and are rapidly cleared. The administration of high systemic doses also comes with the risk of haemorrhagic adverse effects. Therefore, many high-risk CVD patients have been left untreated because of their risk of bleeding.

My PhD research aims to overcome the above challenges by developing novel targeted therapeutic agents and nanoparticles carriers for treating CVDs. The new targeted nanoparticles systems for drug delivery will:

1. Bind to the biomarkers specific and home to the site of disease.
2. Reduce the systemic drug concentration required.
3. Incorporate a high payload of anti-thrombotic or fibrinolytic drugs in the nanoparticles and achieve controlled release, thereby reducing unwanted side effects.